Castle Biosciences Launches Test to Guide Atopic Dermatitis Treatment Selection

Clinical Lab Products·Nov 12

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

Castle Biosciences has launched a test to guide treatment selection for atopic dermatitis. The test, known as AdvanceAD-Tx, is a gene expression test that has received approval from the New York State Department of Health. Details of the test include that it involves a 487-gene analysis, and it has been recognized with a 2026 MedTech Breakthrough Award for genomics innovation.

Full coverage

New York State Approves Castle Biosciences’ Gene Expression Test to Guide Atopic Dermatitis Treatment

Clinical Lab Products·Jul 16

Castle Biosciences Launches 487-Gene Test for AD Care

Dermatology Times·Nov 4

Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test

PR Newswire·Jul 14

Castle Biosciences Rolls Out AdvanceAD-Tx

The Dermatology Digest·Nov 4

Castle Biosciences: Interview With Founder, CEO, And President Derek Maetzold About The Molecular Diagnostics Company

Pulse 2.0·Mar 5

Precision Medicine in AD: Castle Biosciences’ Pipeline AD Test Aims to Change the Way Your Patients Are Treated

The Dermatology Digest·Oct 25

New Gene Expression Test Helps Guide Atopic Dermatitis Treatment Decisions

Clinical Lab Products·Feb 20

Castle Biosciences' AdvanceAD-Tx™ Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation

Yahoo Finance·May 12

View original report at Clinical Lab Products ↗

Fetching the latest headlines…